Registry for patients with metastatic lobular breast cancer
Official title: Improving Survival for Those With Metastatic Lobular Breast Cancer Through Development of the Multi-center PLUMB Registry-a Prospective Study of LobUlar Metastatic Breast Cancer
Run by University of California, San Francisco · NCT05964504 · Data updated 2026-11-12
This study is collecting information from patients with metastatic lobular breast cancer to see how they respond to treatments and understand their overall health over time.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | University of California, San Francisco Academic / other |
| Locations | 4 sites (San Diego, California and 3 other locations) |
| Status | Recruiting |
| Started | December 20, 2023 |
| Main results expected | February 28, 2036 |
| Study ends | February 28, 2036 |
| Registry record updated | November 6, 2026 |
| Trial ID | NCT05964504 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with histologically confirmed invasive lobular carcinoma.
✕Probably not a fit
Patients with early-stage breast cancer (Stage I-III) or those without lobular histology on tumor biopsy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational registry aims to collect data from patients with invasive lobular carcinoma (ILC) of the breast to develop a specific response assessment tool. The study will evaluate the feasibility of a histologic-based registry and analyze treatment patterns, natural history, and overall survival using real-world data. Participants will be recruited during clinic visits and will provide blood samples at various evaluation points, with follow-up until loss to follow-up, death, or withdrawal from the registry.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and treatment strategies for patients with metastatic lobular breast cancer.
How similar studies have gone: While this approach is observational and builds on existing knowledge, similar studies have shown promise in understanding metastatic breast cancer dynamics.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Histologically confirmed invasive lobular carcinoma. Mixed lobular/ductal cancer is allowed. 2. Age \>=18 years 3. Any receptor subtype. 4. Ability to understand a written informed consent document, and the willingness to sign it. Exclusion Criteria: 1. Stage I-III breast cancer. 2. Lack of lobular histology on tumor biopsy. 3. Other active cancer (prior treated cancer with no current evidence of disease is allowed).
Where it's running
-
University of California, San Diego
San Diego, California, United States Recruiting -
University of California, San Francisco
San Francisco, California, United States Recruiting -
Abramson Cancer Center
Philadelphia, Pennsylvania, United States Recruiting -
MD Anderson Cancer Center
Houston, Texas, United States Recruiting
Study contacts
- Principal investigator: Rita Mukhtar, MD — University of California, San Francisco
- Study coordinator: Venezia Garza
- Email: venezia.garza@ucsf.edu
- Phone: 415-353-8732
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
18F-FES PET/MRI to find hidden disease in invasive lobular breast cancer
This study tests whether adding 18F-FES PET/MRI can reveal more disease in lobular breast cancer than standard imaging alone.
-
PRT13722 in advanced HR+/HER2- breast cancer
This early study tests PRT13722, by itself and with standard therapies, to see if it is safe and has any signs of activity in adults with HR+/HER2- breast cancer who have progressed on prior treatments.
-
Personalized treatment after endocrine therapy failure in metastatic breast cancer
The study tests whether using a patient’s fresh tumor sample to try different drugs outside the body can help pick the next therapy for hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on endocrine therapy.
-
SSGJ-612 plus a HER2-targeted ADC in HR-positive, HER2-low metastatic breast cancer
This phase II study tests whether adding SSGJ-612 to a HER2-targeted antibody-drug conjugate helps people with HR-positive, HER2-low or ultralow metastatic breast cancer.
-
SMP-656 in HER2-positive advanced breast cancer after ADC therapy
This trial tests whether SMP-656 given by IV every 3 weeks can help people with HER2-positive locally advanced or metastatic breast cancer who progressed after a HER2-targeted antibody-drug conjugate.
-
Entinostat with Pyrotinib and Endocrine Therapy in HER2-positive, HR-positive Advanced Breast Cancer after Trastuzumab Failure
This study tests whether adding entinostat to pyrotinib and hormone therapy is safe and helps patients with advanced HR+/HER2+ breast cancer who progressed after trastuzumab.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.